Denali Therapeutics Inc. Accumulated Other Comprehensive Income
Denali Therapeutics Inc. (DNLI) had Accumulated Other Comprehensive Income of -$1.97 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.97M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$682.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $682.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.10M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$1.97M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$682.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $682.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.10M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $939.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $2.04M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $2.02M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.53M 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$2.66M 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$1.30M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $643.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | -$651.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$1.44M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$2.52M 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$6.89M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$11.85M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$12.27M 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$9.25M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$2.50M 10-K · filed 2023-02-27 |
| 2021-09-30 | -$521.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$368.00K 10-Q · filed 2021-08-04 |
| 2021-03-31 | -$232.00K 10-Q · filed 2021-05-05 |
| 2020-12-31 | -$245.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $11.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $551.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $835.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $350.00K 10-K · filed 2021-02-26 |
| 2019-09-30 | $562.00K 10-Q · filed 2019-11-06 |
| 2019-06-30 | $879.00K 10-Q · filed 2019-08-06 |
| 2019-03-31 | $332.00K 10-Q · filed 2019-05-08 |
| 2018-12-31 | -$649.00K 10-K · filed 2020-02-27 |
| 2018-09-30 | -$1.42M 10-Q · filed 2018-11-08 |
| 2018-06-30 | -$1.49M 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$1.29M 10-Q · filed 2018-05-11 |
| 2017-12-31 | -$368.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |